ATWLPPR Inhibitor – Peptide TFA

ATWLPPR Peptide TFA is a selective neuropilin-1 inhibitor and inhibits VEGF165 binding to NRP-1. It has the potential in reducing the early retinal damage caused by diabetes.

Starzec A, et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 2007 Dec;28(12):2397-402.
Starzec A, et al. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. Peptides. 2007 Dec;28(12):2397-402.
Wang J, et al. The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress. PLoS One. 2015 Nov 10;10(11):e0142571.
Wang J, et al. The Neuropilin-1 Inhibitor, ATWLPPR Peptide, Prevents Experimental Diabetes-Induced Retinal Injury by Preserving Vascular Integrity and Decreasing Oxidative Stress. PLoS One. 2015 Nov 10;10(11):e0142571.

Small volumes of ATWLPPR, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5752736 is an inhibitor targeting ATWLPPR. Also known as ATWLPPR Peptide TFA.